Literature DB >> 30391882

Vitamin E inhibits cyclosporin A-induced CTGF and TIMP-1 expression by repressing ROS-mediated activation of TGF-β/Smad signaling pathway in rat liver.

Amany Balah1, Omnia Ezzat2, El-Sayed Akool3.   

Abstract

Cyclosporin A (CsA) is the most common immunosuppressive drug used in organ transplantation. However, the clinical use of CsA is often limited by several side effects including hepatotoxicity. In the present study, it was found that administration of CsA causes a rapid activation of TGF-β/Smad signaling cascade and subsequent expression of the profibrotic genes connective tissue growth factor (CTGF) and tissue inhibitors of matrix metallproteinases-1 (TIMP-1) in rat liver. In addition, Smad phosphorylation and subsequent CTGF and TIMP-1 expression were markedly reduced in the presence of neutralizing monoclonal TGFβ1-3 antibody. Furthermore, CsA administration significantly increased the serum levels of the liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) as well as lipid peroxidation in hepatic tissues. Moreover, significant reduction in the hepatic content of reduced glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT) was observed in CsA-alone-treated animals. Histopathological changes were also observed in CsA-alone-treated rats. Pretreatment of animals with Vitamin E (Vit E) before CsA administration significantly reduced TGF-β level as well as Smad phosphorylation and subsequent CTGF and TIMP-1 expression. Furthermore, administration of PEG-SOD clearly attenuated TGF-β/Smad signaling induced by CsA. Moreover, concomitant administration of Vit E along with CsA significantly ameliorated the histopathological changes and improved liver function as well as the antioxidant capacity. Finally, this study shows that the immunosuppressive efficiency of CsA was not altered in the presence of Vit E. These data may support the concept of using antioxidant therapy as a valuable approach for the prevention of CsA-induced tissue fibrosis.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cyclosporin A; Liver; TGF-β/Smad signaling; Vitamin E

Mesh:

Substances:

Year:  2018        PMID: 30391882     DOI: 10.1016/j.intimp.2018.09.033

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  8 in total

1.  Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2.

Authors:  Reda G Yousef; Wagdy M Eldehna; Alaa Elwan; Abdelaziz S Abdelaziz; Ahmed B M Mehany; Ibraheem M M Gobaara; Bshra A Alsfouk; Eslam B Elkaeed; Ahmed M Metwaly; Ibrahim H Eissa
Journal:  Molecules       Date:  2022-06-24       Impact factor: 4.927

2.  Cyclosporin A activates human hepatocellular carcinoma (HepG2 cells) proliferation: implication of EGFR-mediated ERK1/2 signaling pathway.

Authors:  Mohammed E Abo-El Fetoh; Gouda K Helal; I G Saleh; M Ewees; Mohamed ElShafey; Mohamed R Elnagar; El-Sayed Akool
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-01-06       Impact factor: 3.000

3.  The involvement of TGF-β1 /FAK/α-SMA pathway in the antifibrotic impact of rice bran oil on thioacetamide-induced liver fibrosis in rats.

Authors:  Rehab F Abdel-Rahman; Hany M Fayed; Gihan F Asaad; Hanan A Ogaly; Alyaa F Hessin; Abeer A A Salama; Sahar S Abd El-Rahman; Mahmoud S Arbid; Marawan Abd Elbaset Mohamed
Journal:  PLoS One       Date:  2021-12-29       Impact factor: 3.240

4.  New quinoxaline-based VEGFR-2 inhibitors: design, synthesis, and antiproliferative evaluation with in silico docking, ADMET, toxicity, and DFT studies.

Authors:  Mohammed M Alanazi; Hazem Elkady; Nawaf A Alsaif; Ahmad J Obaidullah; Hamad M Alkahtani; Manal M Alanazi; Madhawi A Alharbi; Ibrahim H Eissa; Mohammed A Dahab
Journal:  RSC Adv       Date:  2021-10-12       Impact factor: 4.036

5.  Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, in silico studies, and antiproliferative evaluation.

Authors:  Mohammed S Taghour; Hazem A Mahdy; Maher H Gomaa; Ahmed Aglan; Mahmoud Gomaa Eldeib; Alaa Elwan; Mohammed A Dahab; Eslam B Elkaeed; Aisha A Alsfouk; Mohamed M Khalifa; Ibrahim H Eissa; Hazem Elkady
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

6.  Modified Benzoxazole-Based VEGFR-2 Inhibitors and Apoptosis Inducers: Design, Synthesis, and Anti-Proliferative Evaluation.

Authors:  Alaa Elwan; Abdallah E Abdallah; Hazem A Mahdy; Mohammed A Dahab; Mohammed S Taghour; Eslam B Elkaeed; Ahmed B M Mehany; Ahmed Nabeeh; Mohammed Adel; Aisha A Alsfouk; Hazem Elkady; Ibrahim H Eissa
Journal:  Molecules       Date:  2022-08-08       Impact factor: 4.927

7.  Discovery of new 1H-pyrazolo[3,4-d]pyrimidine derivatives as anticancer agents targeting EGFRWT and EGFRT790M.

Authors:  Ahmed A Gaber; Mohamed Sobhy; Abdallah Turky; Hanan Gaber Abdulwahab; Ahmed A Al-Karmalawy; Mostafa A Elhendawy; Mohamed M Radwan; Eslam B Elkaeed; Ibrahim M Ibrahim; Heba S A Elzahabi; Ibrahim H Eissa
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

8.  Anti-cancer and immunomodulatory evaluation of new nicotinamide derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: in vitro and in silico studies.

Authors:  Reda G Yousef; Alaa Elwan; Ibraheem M M Gobaara; Ahmed B M Mehany; Wagdy M Eldehna; Souad A El-Metwally; Bshra A Alsfouk; Eslam B Elkaeed; Ahmed M Metwaly; Ibrahim H Eissa
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.